On January 13, 2025, Roivant Science Ltd made two major purchases, $336.9 million for each. The first purchase was the shares of Immunovant Inc. (NASDAQ:IMVT) and the companys own stock ROIV.
In the first transaction, Sciences Roivant served both as a director and 10% owner of Immunovant Inc., it acquired 16,845,010 shares of IMVT for $20 per share. Roivant now holds 96,650,341 shares of Immunovant after the insider purchase of $336.9 million.
Immunovant is a clinical-stage biopharmaceutical company focused on the development of treatments for autoimmune diseases through monoclonal antibodies targeting the neonatal Fc receptor FcRn.
With $635 million of cash and cash equivalent in the end of 2024, the financial position of Immunovant gives a decent signal that the company can pay its $250 million annual business expenses when it had zero sales revenue for years since inception in 2018.
Sciences Roivant on the latter purchase executed a $336.9 million stock buyback under a $1.5 billion repurchase program that was authorized. Shares repurchase returns value to shareholder and improving the investor confidence.
Industry analysts are waiting and watching to see how these investments will position both companies to become more profitable.
You can make more informed investment decisions by visiting GuruFocus now and deep dive into Immunovant and Roivant Sciences' performance with charts, breakdowns, insiders, screeners and more!
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。